Oral GLP-1 pills explained: orforglipron and oral semaglutide

For most of the GLP-1 era, 'starting a GLP-1' has meant learning to give yourself a weekly injection. That is no longer the only option. Two oral GLP-1s are now approved for weight management and sold in US pharmacies: the Wegovy pill, a 25 mg oral semaglutide tablet the FDA approved in December 2025¹², and Foundayo (orforglipron), approved on April 1, 2026 as the first small-molecule GLP-1 built from the ground up to be swallowed¹⁰. That is one of the biggest structural shifts in this space since tirzepatide arrived. This brief lays out what each pill is, what the evidence shows, and what swallowing a GLP-1 does — and doesn't — change for you. It's market and evidence context, not medical advice.

Two very different 'pills'

The confusing part is that 'oral GLP-1' refers to two different kinds of drug. The first is oral semaglutide — the same peptide molecule as injectable semaglutide, reformulated into a tablet with an absorption enhancer so enough of it survives the stomach. The second is orforglipron, a brand-new small-molecule (non-peptide) GLP-1 receptor agonist designed from the ground up to be swallowed. They both hit the same receptor, but they behave differently in ways that matter to a real patient.

Oral semaglutide: the tablet that already exists

A low-dose oral semaglutide tablet (marketed as Rybelsus) has been FDA-approved for type 2 diabetes for years, and its pivotal monotherapy trial showed meaningful A1c and weight reductions versus placebo⁸⁷. The catch is how you have to take it: on an empty stomach, with no more than about 4 ounces of plain water, then wait roughly 30 minutes before eating, drinking, or taking other medications⁸. Skip that ritual and the drug barely absorbs. That's the price of putting a peptide into a pill.

The newer development is dose, and it has now cleared review. Researchers first tested a much higher 50 mg oral semaglutide tablet specifically for weight management in people without diabetes: in the OASIS 1 trial, that tablet produced a mean weight reduction of about 15.1% over 68 weeks, versus about 2.4% on placebo⁶ — numbers in the same territory as the injections. The dose that actually reached the market is 25 mg, studied in OASIS 4¹¹; Novo Nordisk reports it produced about 16.6% mean weight loss when treatment was adhered to, in adults with obesity or overweight plus a related condition. The FDA approved that tablet in December 2025 as the Wegovy pill — the first oral GLP-1 cleared for weight management — and it reached US pharmacies the following month¹². The fasting-and-water routine comes with it.

Orforglipron: the pill built to be a pill

Orforglipron is the one generating headlines, because it's a small molecule rather than a peptide. Practically, that means it doesn't need the strict empty-stomach, limited-water routine — it's designed to be taken once daily without those food and water restrictions¹. For a lot of people, 'a pill you just take' is a very different proposition from 'a pill with a 30-minute ritual.'

The efficacy signal is real but should be read carefully. In ATTAIN-1, a phase 3 obesity trial, once-daily orforglipron at its top 36 mg dose produced a mean weight reduction of about 11.2% over 72 weeks, versus about 2.1% on placebo, and moved waist circumference, blood pressure, triglycerides, and non-HDL cholesterol in the right direction¹. That's a solid result — and, on its face, a more modest average than the ~15–21% headline figures from the strongest injectable trials. A pill you'll actually take can still beat a shot you skip, but the trial averages don't crown orforglipron the most powerful option in the class.

What the diabetes trials add

Beyond obesity, orforglipron has a growing type 2 diabetes evidence base. An early dose-ranging trial established that it lowered A1c and weight across a range of doses², and later phase 3 studies pitted it against real comparators: head-to-head against oral semaglutide³, against the SGLT2 inhibitor dapagliflozin⁴, and as an add-on to insulin glargine⁵. Taken together, that's an unusually broad late-stage program for a new oral agent — which is part of why it's treated as a potential category-changer rather than a niche entry.

The side effects don't disappear in pill form

A pill is still a GLP-1, and the tolerability story travels with the molecule, not the delivery format. A meta-analysis of orforglipron trials found the familiar class pattern — nausea, vomiting, and diarrhea — occurring in a dose-dependent way, which is why these drugs are titrated up slowly⁹; constipation is another common GLP-1 class effect patients report. The same boxed warnings and contraindications that apply to the injectable GLP-1s (including the thyroid C-cell tumor warning seen in rodent studies) apply to the oral versions of the same molecules. Swallowing it instead of injecting it changes the convenience, not the safety profile you screen for — including the dry-mouth and taste-change reports covered in "Ozempic teeth", which aren't specific to needles.

Where approval actually stands

This is the part that moved fastest, so check the date on anything else you read about it. Both weight-management pills are approved products now, not pipeline candidates. The Wegovy pill (oral semaglutide 25 mg) was approved in December 2025 and reached US pharmacies the following month¹². Foundayo (orforglipron) was approved on April 1, 2026 — the FDA's fastest clearance of a new molecular entity since 2002 — for adults with obesity, or adults with overweight plus at least one weight-related condition, alongside a reduced-calorie diet and more physical activity¹⁰. It is taken once daily with or without food, and it carries the same boxed warning about thyroid C-cell tumors seen in rodent studies that the injectable GLP-1s carry¹⁰. Low-dose oral semaglutide (Rybelsus) remains approved for type 2 diabetes, which is a different indication from weight management⁸. What still deserves scrutiny is a seller offering a compounded 'oral GLP-1': a pharmacy-made tablet or dissolving strip is not either approved pill, whatever molecule is named on it. We track approvals and launches as they land in our provider briefs.

What a pill actually changes for you

Now that both pills are on the market, what changes? Convenience and access, mostly. A daily oral option lowers the needle barrier for people who won't inject, and pills are generally easier to manufacture and distribute than sterile injectables — which, over time, could ease the supply crunch that has defined this market and put downward pressure on price. We unpack those forces in why GLP-1 prices move and GLP-1 shortages and supply. What a pill probably won't change: the need for real clinical oversight, honest pricing, and a legitimate pharmacy behind it.

How to think about it as a shopper

Oral GLP-1s are now something you can be prescribed, so the shopping question is a real one rather than a hypothetical. There is still a third category worth separating out: compounded oral semaglutide, which is neither Rybelsus nor either approved weight-management pill but a pharmacy-made version sold by cash-pay telehealth providers — MyDrHank's oral semaglutide line is one of the few we track that publishes a price for it. Synergy Rx prices both molecules as dissolving tablets too, and its ODT ladder is a useful warning: the multi-month bundles there work out fractionally more per month than paying monthly, so the needle-free route carries no bulk discount at all. The cleanest counter-example we track is SkinnyRx, where the tirzepatide tablet costs exactly what the tirzepatide injection costs — $399 a month, and the same figure at every one of its four commitment terms — so choosing the needle-free route there is priced at neither a premium nor a discount. It is not FDA-approved as a product, so read it as a compounded option that happens to be needle-free, not as an approved pill. The same instinct — take a molecule that works by injection and put it in a capsule — has spread well past GLP-1s, and it does not travel well: Rehydra+ sells BPC-157, KPV and tesamorelin in oral form, routes whose bioavailability is not established for those peptides. "Oral" is a claim about delivery, and delivery is most of whether a molecule reaches you at all. If you're choosing a provider today, the molecules that matter are the injectable ones — compare how each provider prices them in our provider briefs and start with the 5-minute provider checklist. If tirzepatide is the injectable you're weighing against a pill, see the current tirzepatide picture for pricing and footprint. If you're weighing 'stronger vs. more convenient,' read semaglutide vs tirzepatide for the injectable benchmark these pills are measured against, and keep compounded vs brand-name GLP-1 in mind, because a compounded 'oral GLP-1' is exactly the kind of product gray-market sellers push hardest. You can see how every provider scores on [the ranking](/#rankings) and how we weigh them in our Brief Score. Decisions about your own treatment belong with a clinician.